Szvetko Attila L, Jones Ashleigh, Mackenzie Jason, Tajouri Lotti, Csurhes Peter A, Greer Judith M, Pender Michael P, Griffiths Lyn R
Genomics Research Centre, Griffith Institute for Health and Medical Research, School of Medical Science, Griffith University, Gold Coast campus, PMB50 GCMC Qld 9726, Queensland, Australia.
Brain Res. 2009 Feb 19;1255:148-52. doi: 10.1016/j.brainres.2008.12.017. Epub 2008 Dec 16.
Multiple sclerosis (MS) is a common cause of neurological disability in young adults. The disease generally manifests in early to middle adulthood and causes various neurological deficits. Autoreactive T lymphocytes and their associated antigens have long been presumed important features of MS pathogenesis. The Protein tyrosine phosphatase receptor type C gene (PTPRC) encodes the T-cell receptor CD45. Variations within PTPRC have been previously associated with diseases of autoimmune origin such as type 1 diabetes mellitus and Graves' disease. We set out to investigate two variants within the PTPRC gene, C77G and C772T in subjects with MS and matched healthy controls to determine whether significant differences exist in these markers in an Australian population. We employed high resolution melt analysis (HRM) and restriction length polymorphism (RFLP) techniques to determine genotypic and allelic frequencies. Our study found no significant difference between frequencies for PTPRC C77G by either genotype (Chi(2)=0.65, P=0.72) or allele (Chi(2)=0.48, P=0.49). Similarly, we did not find evidence to suggest an association between PTPRC C772T by genotype (Chi(2)=1.06, P=0.59) or allele (Chi(2)=0.20, P=0.66). Linkage disequilibrium (LD) analysis showed strong linkage disequilibrium between the two tested markers (D'=0.9970, SD=0.0385). This study reveals no evidence to suggest that these markers are associated with MS in the tested Australian Caucasian population. Although the PTPRC gene has a significant role in regulating CD4+ and CD8+ autoreactive T-cells, interferon-beta responsiveness, and potentially other important processes, our study does not support a role for the two tested variants of this gene in MS susceptibility in the Australian population.
多发性硬化症(MS)是年轻成年人神经功能残疾的常见病因。该疾病通常在成年早期至中期出现,并导致各种神经功能缺损。自身反应性T淋巴细胞及其相关抗原长期以来一直被认为是MS发病机制的重要特征。蛋白酪氨酸磷酸酶受体C型基因(PTPRC)编码T细胞受体CD45。PTPRC内的变异先前已与自身免疫性疾病如1型糖尿病和格雷夫斯病相关联。我们着手研究MS患者和匹配的健康对照中PTPRC基因的两个变异体C77G和C772T,以确定在澳大利亚人群中这些标记物是否存在显著差异。我们采用高分辨率熔解分析(HRM)和限制性片段长度多态性(RFLP)技术来确定基因型和等位基因频率。我们的研究发现,无论是基因型(卡方=0.65,P=0.72)还是等位基因(卡方=0.48,P=0.49),PTPRC C77G的频率之间均无显著差异。同样,我们也没有发现证据表明PTPRC C772T的基因型(卡方=1.06,P=0.59)或等位基因(卡方=0.20,P=0.66)之间存在关联。连锁不平衡(LD)分析显示两个测试标记物之间存在强连锁不平衡(D'=0.9970,标准差=0.0385)。这项研究没有证据表明这些标记物与所测试的澳大利亚白种人群中的MS相关。尽管PTPRC基因在调节CD4+和CD8+自身反应性T细胞、干扰素-β反应性以及潜在的其他重要过程中具有重要作用,但我们的研究不支持该基因的两个测试变异体在澳大利亚人群MS易感性中起作用。